A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.